Borderline Resectable Pancreatic Cancer Clinical Trial
Official title:
Prospective Phase II Single-arm Study of Neoadjuvant Nab-Paclitaxel and S-1 in Patients With Borderline Resectable Pancreatic Cancer
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer. A total of 60 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1, for a maximum of 4 cycles prior to pancreatectomy. The primary endpoint is R0 resection rate, the secondary endpoints include overall survival and response rate.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04617821 -
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
|
Phase 3 | |
| Suspended |
NCT04090463 -
IORT on Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT04698915 -
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06384560 -
Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03443921 -
Divestment for Artery-involved Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT06345300 -
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
|
Phase 2 | |
| Active, not recruiting |
NCT02717091 -
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT02241551 -
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04855331 -
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
|
N/A |